民生健康 reported revenue of ¥0.54B for the period ended 2026-06-30, +15.8% year on year. Net income was ¥0.08B, a 15.6% net margin on a 55.2% gross margin. The largest revenue line is 维生素与矿物质补充剂系列 at 84% of the total. Free cash flow for the period was ¥-0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.54B | +15.8% |
| Gross profit | ¥0.30B | — |
| Operating income | ¥0.10B | — |
| Net income | ¥0.08B | +1.3% |
| Gross margin | 55.2% | Net margin 15.6% |
| Revenue Q/Q | -31.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 维生素与矿物质补充剂系列 | ¥0.45B | 84.1% |
| 其他主营业务 | ¥0.08B | 15.6% |
| 其他(补充) | ¥0.00B | 0.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.24B | 44.8% |
| R&D | ¥0.01B | 2.3% |
| SG&A | ¥0.18B | 33.5% |
| Tax & other | ¥0.02B | 3.1% |
| Item | Amount |
|---|---|
| Total assets | ¥2.10B |
| Total liabilities | ¥0.37B |
| Shareholders' equity | ¥1.73B |
| Equity / assets | 82.3% |
| Operating cash flow | ¥0.02B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥-0.00B |
| Cash conversion (OCF / net income) | 163% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中机认检 ・ 金凯生科 ・ 固高科技 ・ 德福科技 ・ 智信精密 ・ 尚水智能 ・ 港通医疗 ・ 中远通 ・ 陕西华达 ・ 长华化学 ・ 舜禹股份 ・ 万邦医药
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies